Virus-Like Particle Vaccine Market Latest Report 2023-2031 | InsightAce Analytic

Companies covered in this report are Novavax, GlaxoSmithKline, Merck & Co., Medicago, Dynavax Technologies, Cytos Biotechnology, iBio, Sanofi Pasteur, Bavarian Nordic, GeoVax Labs

Jersey City, NJ, Nov. 16, 2023 (GLOBE NEWSWIRE) — InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Virus-Like Particle Vaccine Market– (By Application Type (Infectious Diseases, Cancer Immunotherapy, Others), By Stage (Pre-clinical Research Stage, Approved Vaccines), By Distribution Channel (Healthcare Providers, Government Vaccination Programs, Retail Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”

According to the latest research by InsightAce Analytic, the Global Virus-Like Particle Vaccine Market is expected to show a CAGR of 8.24% during a forecast period of 2023-2031.

Virus-like particle (VLP) vaccinations are those that have the structure of viruses but do not contain infectious genetic material. They are a safe and effective method of stimulating an immune response to certain diseases, such as viruses. The growing emphasis on preventative healthcare measures, such as vaccination, promotes demand for novel and effective vaccines such as VLPs.

Furthermore, rising governmental and private sector investments in VLP vaccine research and development stimulate innovation and propel the industry ahead. The rising occurrence of infectious diseases such as HPV, hepatitis B, and certain malignancies drives the need for effective vaccines, boosting growth in the VLP vaccine market. Public awareness campaigns and vaccination education increase the acceptability and demand for VLP vaccines, increasing market growth and adoption rates. These growth factors work together to propel the VLP vaccine market forward, making it a promising and active sector within the larger field of vaccine development.

Free PDF Report Brochure @

Recent Developments:

  • In March 2020, iBio, Inc. announced that the immunization studies for its SARS-CoV-2 Virus-Like Particle (“VLP”) program (“IBIO-200”) were underway at Texas A&M University System (“TAMUS”) laboratories.   The work was performed as part of the Master Joint Development Agreement established between iBio and TAMUS in 2016. 

List of Prominent Players in the Virus-Like Particle Vaccine Market:

  • Novavax
  • GlaxoSmithKline
  • Merck & Co.
  • Medicago
  • Dynavax Technologies
  • Cytos Biotechnology
  • iBio
  • Sanofi Pasteur
  • Bavarian Nordic
  • GeoVax Labs
  • Others

Curious About This Latest Version of The Report? Enquiry Before Buying:

Virus-Like Particle Vaccine Market Report Scope

Report Attribute Specifications
Growth Rate CAGR CAGR of 8.24 % from 2023 to 2031
Quantitative Units Representation of revenue in US$ Million and CAGR from 2023 to 2031
Historic Year 2019 to 2022
Forecast Year 2023-2031
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Application Type, Stage, Distribution Channel
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia
Competitive Landscape Novavax, GlaxoSmithKline, Merck & Co., Medicago, Dynavax Technologies, Cytos Biotechnology, iBio, Sanofi Pasteur, Bavarian Nordic, GeoVax Labs and Others
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing and Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Market Dynamics:

Several variables influence the growth and evolution of the worldwide virus-like particle vaccine market. Increasing public knowledge of the benefits of vaccination in preventing infectious diseases has increased vaccine demand. Furthermore, advances in biotechnology, such as genetic engineering and protein expression technologies, have made VLP production more cost-effective and efficient. This has decreased the barriers to vaccine development. Furthermore, virus-like particle-based therapies for topical and emerging viral diseases and cancer are still in the works, presenting lucrative prospects for market expansion. 

Several challenges have the potential to hinder the market’s growth. VLP vaccine production can be technically difficult and time-consuming. When compared to other standard vaccination types, the necessity for genetic engineering, protein expression, and purification techniques can make development more difficult. VLP vaccine manufacture frequently involves advanced biotechnology techniques that might be costly. These expenses may make VLP vaccinations less affordable, particularly in low-income areas.

Regional Trends:
The North America Virus-Like Particle Vaccine Market is expected to register a major market share in terms of revenue, and it is projected to grow at a high CAGR in the near future. The region has a strong medical system and significant healthcare spending, which facilitates vaccine research, uptake, and distribution. Furthermore, significant research and development resources in the United States and Canada enable the creation of novel VLP vaccines. Furthermore, Asia Pacific is predicted to develop significantly in the worldwide virus-like particle vaccine market. The region’s vast and densely populated countries, such as China and India, generate a significant demand for vaccines to prevent infectious diseases. Furthermore, governments in APAC nations have prioritized public health and immunization programs, offering financing and regulatory assistance.

For More Customization @

Segmentation of Virus-Like Particle Vaccine Market-

By Application Type-

  • Infectious Diseases
  • Cancer Immunotherapy
  • Others.

By Stage-

  • Pre-clinical Research Stage
  • Approved Vaccines

By Distribution Channel-

  • Healthcare Providers
  • Government Vaccination Programs
  • Retail Pharmacies

By Region-

North America-

  • The US
  • Canada
  • Mexico


  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

About Us:

InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.

Follow Us @

Subscribe Our Exclusive Newsletters @

CONTACT: Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: Site Visit:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.